Premier (NASDAQ:PINC) Stock

Premier

Premier Inc is a Charlotte, North Carolina-based technology-driven healthcare improvement company, uniting an alliance of United States (U.S.) hospitals, health systems, and other providers and organizations to transform healthcare. The company's revenue is all sourced domestically and is reported in two business segments: the supply chain services and the consulting and technology platform of performance services. It generates the majority of its revenue from the supply chain services segment.

Premier Inc

Canaccord Genuity analyst Richard Close maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Hold and raises the price target from $19 to $22.

News

Price Target

Analyst Ratings

PINC

Canaccord Genuity Maintains Hold on Premier, Raises Price Target to $22

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)</h3>
<ul>
<li>Dividend Yield: 5.59%</li>
<li>Piper Sandler analyst David Amsellem reiterated a Neutral rating and cut the price target from $14 to $10 on March 5, 2025. This analyst has an accuracy rate of 73%.</li>
<li>B of A Securities analyst Jason Gerberry maintained an Underperform rating and slashed the price target from $11 to $10 on Feb. 28, 2025. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: On April 14, Viatris named Hemanth J. Varghese as Chief Strategy Officer.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">VTRS news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="918" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49.png" alt="" class="wp-image-902820" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050532/image-49-768x701.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.95%</li>
<li>Piper Sandler analyst David Amsellem initiated coverage on the stock with an Overweight rating and a price target of $65 on April 22, 2025. This analyst has an accuracy rate of 73%.</li>
<li>UBS analyst Trung Huynh maintained a Neutral rating and slashed the price target from $60 to $54 on April 11, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On April 24, Bristol Myers Squibb reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 billion.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">latest BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="907" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50.png" alt="" class="wp-image-902821" style="width:561px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050614/image-50-768x714.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Premier, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>)</h3>
<ul>
<li>Dividend Yield: 4.10%</li>
<li>Baird analyst Eric Coldwell maintained a Neutral rating and cut the price target from $20 to $19 on Feb. 5, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Benchmark analyst Bill Sutherland downgraded the stock from Buy to Hold on Aug. 26, 2024. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: The company is expected to announce quarterly earnings today.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">latest PINC news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="906" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51.png" alt="" class="wp-image-902822" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06050643/image-51-768x714.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Markets

Trading Ideas

VTRS

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

WIIM

Premier shares are trading higher after the company reported better-than-expected Q3 results and raised its FY25 adjusted EPS guidance.

Guidance

Premier Raises FY25 Adj EPS Guidance From $1.26 - $1.34 To $1.37 - $1.43 Vs. $1.29 Est.

Premier Updates FY25 Net Revenue Excluding Contigo Health Outlook From $940B - $1.01B to $955M - $995M

Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.30 by 46.67 percent. This is a 20 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $261.38 million which beat the analyst consensus estimate of $240.45 million by 8.71 percent. This is a 23.71 percent decrease over sales of $342.60 million the same period last year.

Earnings

Earnings Beats

Premier Q3 Adj. EPS $0.44 Beats $0.30 Estimate, Sales $261.38M Beat $240.45M Estimate

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

J.P. Morgan analyst Anne E. Samuel reiterated the Neutral rating on Premier, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) on Tuesday<a target="_blank" href="https://www.benzinga.com/quote/PINC/analyst-ratings" rel="noreferrer noopener">, with a price forecast of $19.</a>
The analyst notes that Premier&#8217;s stable business is supported by its ownership structure, leading to longer-term contracts typically lasting five to seven years.
Meanwhile, the company&#8217;s growth is closely tied to hospital utilization trends, which has historically led to an expected long-term growth rate of mid-single-digit to high-single-digit percentage increases in both revenue and profit, Samuel adds.
In the short term, though, Premier has experienced weaker performance due to factors like the end of COVID-related stockpiling, rising inflation, and budget constraints faced by hospitals.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44610548/trumps-auto-tariffs-could-crush-demand-blow-26-billion-hole-in-industry-profits" rel="noreferrer noopener">Trump&#8217;s Auto Tariffs Could Crush Demand, Blow $26 Billion Hole In Industry Profits</a>
The analyst highlights several risks that could lead to PINC shares underperforming compared to others.
These risks include a potential slowdown in growth within the Group Purchasing Organization business, due to a weak macroeconomic environment, reduced hospital utilization, and the increasing trend of hospitals forming their own GPOs, as well as heightened competition in the market, the analyst cautions.
Additionally, Samuel adds that the Performance Services business faces significant competition, particularly from larger companies with more capital.
Meanwhile, if hospital utilization trends improve, growth could accelerate, potentially making the analyst&#8217;s current estimates and price target too low, Samuel notes.
Price Action: PINC shares are trading higher by 0.05% to $19.49 at last check Wednesday.
Read now:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44544217/chicken-tax-2-0-bank-of-america-flags-3-million-sales-at-risk-after-auto-tariffs" target="_blank" rel="noreferrer noopener">Chicken Tax 2.0: Bank Of America Flags 3 Million Sales At Risk After Auto Tariffs</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Equities

Reiteration

Movers

General

Premier Has Stable Business But Analyst Remains Neutral - Here's Why

Premier, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>), a leading technology-driven healthcare improvement company, today announced that it has entered into accelerated share repurchase agreements with JPMorgan Chase Bank, National Association ("JPMorgan") to repurchase an aggregate of $200 million of shares of its Class A common stock (the "ASR program"). The ASR program was authorized under the Company's $1.0 billion share repurchase authorization approved by the Company's Board of Directors (the "Board") in February 2024 (the "Share Repurchase Authorization").

Buybacks

Premier Enters Into $200M Accelerated Share Repurchase Program With JPMorgan Chase Bank, National Association

Piper Sandler analyst Jessica Tassan maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Neutral and lowers the price target from $21 to $19.

Piper Sandler Maintains Neutral on Premier, Lowers Price Target to $19

Baird analyst Eric Coldwell maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Neutral and lowers the price target from $20 to $19.

Baird Maintains Neutral on Premier, Lowers Price Target to $19

Canaccord Genuity analyst Richard Close maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Hold and lowers the price target from $21 to $19.

Canaccord Genuity Maintains Hold on Premier, Lowers Price Target to $19

U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the <a href="https://www.benzinga.com/news/econ-s">world&#8217;s two largest economies.</a>
China responded to President Donald Trump&#8216;s 10% import tariff with targeted countermeasures, including restrictions on key mineral exports to the U.S. and tariffs on American energy products.
Beijing is raising tariffs by 10%-15% on select U.S. imports, including coal, liquefied natural gas, crude oil, agricultural machinery and vehicles. Additionally, China added PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) and Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) to its &#8220;Unreliable Entity List,&#8221; citing the need to &#8220;safeguard national sovereignty, security, and development interests,&#8221; and opened an antitrust investigation on Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>).
Market participants had anticipated a call between Trump and Chinese President Xi Jinping on Tuesday, but media reports indicated the conversation would not happen today.
The trade developments had an immediate impact on oil markets, with West Texas Intermediate crude futures plunging 3% overnight to as low as $70 per barrel. 
Yet, prices rebounded sharply Tuesday morning following reports that Trump is considering issuing a memorandum aimed at inflicting <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43469234/trump-prepares-maximum-pressure-on-iran-oil-jumps-above-73-energy-stocks-rally">maximum economic damage on Iran</a>, potentially leading to a sharp decline in Iranian oil production.
Energy stocks outperformed on the day, while utilities lagged. 
Among individual stocks, Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) rocketed 22% after posting strong earnings and a revenue beat. 
In the commodities market, gold added more than 1%, extending its all-time high, and silver jumped 2.2%. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) declined 2% to $99,000.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,281.54</td>
<td>1.0%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,495.31</td>
<td>0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,029.97</td>
<td>0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,501.00</td>
<td>0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.5% to $600.53.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.1% higher to $444.77.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.9% to $522.81.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1.1% to $226.80.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.9%; the&nbsp;Utilities Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.8%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
Stocks reacting to earnings report included: 
<ul>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>): down 1.53%</li>
<li>PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>): down 4.43%</li>
<li>Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): down 10.49%</li>
<li>PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): down 11.57%</li>
<li>Archer-Daniels-Midland Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>): down 3.58%</li>
<li>KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>): down 7.90%</li>
<li>Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>): up 3.81%</li>
<li>Enterprise Products Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>): down 0.99%</li>
<li>Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>): up 5.85%</li>
<li>Estee Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>): down 16.35%</li>
<li>Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>): down 2.78%</li>
<li>Fox Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>): up 4.00%</li>
<li>Ametek Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>): down 1.00%</li>
<li>Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>): up 5.85%</li>
<li>Ferrari NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>): up 7.62%</li>
<li>Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>): up 10.46%</li>
<li>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>): up 4.71%</li>
<li>Jacobs Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>): down 2.72%</li>
<li>Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>): down 1.51%</li>
<li>Gartner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>): up 0.77%</li>
<li>Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>): down 3.41%</li>
<li>Atkore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>): down 20.50%</li>
<li>Berry Global Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>): up 4.15%</li>
<li>WEC Energy Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>): down 1.52%</li>
<li>Hubbell Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>): down 0.55%</li>
<li>TransDigm Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>): down 1.60%</li>
<li>Graphic Packaging Holding Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>): down 1.76%</li>
<li>CNH Industrial NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNHI#NYSE">CNHI</a>): up 1.71%</li>
<li>Ingredion Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>): down 6.12%</li>
<li>ATI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>): up 7.02%</li>
<li>Ball Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>): down 8.03%</li>
<li>Lancaster Colony Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LANC#NASDAQ">LANC</a>): up 9.27%</li>
<li>Premier Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>): down 15.36%</li>
<li>MPLX LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>): up 2.92%</li>
<li>Oaktree Specialty Lending Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCSL#NASDAQ">OCSL</a>): down 3.42%</li>
<li>PJT Partners Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJT#NYSE">PJT</a>): up 12.77%</li>
<li>Energizer Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENR#NYSE">ENR</a>): down 4.45%</li>
<li>Silicon Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>): down 1.05%</li>
<li>Hamilton Lane Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>): down 0.01%</li>
<li>Madison Square Garden Sports Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGS#NYSE">MSGS</a>): down 3.74%</li>
<li>Pentair Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>): down 1.89%</li>
<li>Amcor Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>): up 3.87%</li>
<li>Inmode Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>): up 2.82%</li>
<li>Willis Towers Watson Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>): down 3.54%</li>
<li>Axalta Coating Systems Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>): up 7.86%</li>
<li>Mesa Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLAB#NASDAQ">MLAB</a>): up 10.48%</li>
</ul>
Major companies reporting their earnings after the close are Alphabet Inc., Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Mondelez International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), Chipotle Mexican Grill Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Prudential Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>), Simon Property Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>), Atmos Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>), Aspen Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>), Carlisle Cos. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>), Fair Isaac Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>), Jack Henry &amp; Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>), Idex Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>) and Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>).
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43468887/robert-f-kennedy-nomination-advances-to-full-senate-vaccine-stocks-drop">Robert F. Kennedy&#8217;s Health Secretary Nomination Advances To Full Senate: Vaccine Stocks Drop</a></li>
</ul>
Photo: Marek Masik via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Commodities

Global

Econ #s

Economics

Tech

$BTC

AMCR

AMGN

AXTA

AZPN

BERY

CNHI

SPDR Dow Jones Industrial Average ETF Trust

ENPH

FICO

FOXA

GOOG

GOOGL

HLNE

HUBB

ILMN

INGR

INMD

JKHY

LANC

MDLZ

MLAB

MPLX

MSGS

OCSL

PLTR

PYPL

RACE

REGN

SLAB

SPOT

US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday?

Premier shares are trading lower after the company reported worse-than-expected Q2 financial results.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Premier, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>)</h3>
<ul>
<li>Dividend Yield: 3.75%</li>
<li>Baird analyst Eric Coldwell maintained a Neutral rating and raised the price target from $19 to $20 on Nov. 6, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Benchmark analyst Bill Sutherland downgraded the stock from Buy to Hold on Aug. 26, 2024. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Feb. 4, Premier posted downbeat quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest PINC <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="887" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071132/image-20.png" alt="" class="wp-image-764631" style="width:544px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071132/image-20.png 887w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071132/image-20-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071132/image-20-768x712.png 768w" sizes="(max-width: 887px) 100vw, 887px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.14%</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and raised the price target from $60 to $65 on Jan. 28. This analyst has an accuracy rate of 71%.</li>
<li>B of A Securities analyst Tim Anderson reinstated a Neutral rating with a price target of $63 on Dec. 10, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Jan. 31, Bristol Myers Squibb received positive CHMP opinion for Opdivo&#xAE; (nivolumab) plus Yervoy&#xAE; (ipilimumab) as a first-line treatment option for adult patients with unresectable or advanced hepatocellular carcinoma.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1">BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="900" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071205/image-21.png" alt="" class="wp-image-764633" style="width:691px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071205/image-21.png 900w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071205/image-21-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071205/image-21-768x706.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 4.75%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and cut the price target from $67 to $60 on Jan. 6. This analyst has an accuracy rate of 68%.</li>
<li>Deutsche Bank analyst George Hill upgraded the stock from Hold to Buy with a price target of $66 on Dec. 3, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Recent News: CVS Health will hold a conference call on Wednesday, Feb. 12, to discuss fourth quarter and full year 2024 financial results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest CVS <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071237/image-22.png" alt="" class="wp-image-764635" style="width:594px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071237/image-22.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071237/image-22-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04071237/image-22-768x711.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock"> Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Fiscal 2025 Guidance
Certain statements in this release, including without limitation, those in this section, are forward-looking statements. For additional information regarding the use and limitations of such statements, refer to "Cautionary Note Regarding Forward-Looking Statements" below.
Based on actual results for the first six months of fiscal 2025 and the current outlook for the remainder of the fiscal year, the company is updating its guidance to the following:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Guidance Metric</td>
<td colspan="1" rowspan="1">
Fiscal 2025
Guidance Range [1] [2] (as of February 4, 2025)
</td>
<td colspan="1" rowspan="1">Previous Fiscal 2025 Guidance Range [1] [2] (as of November 5, 2024)</td>
<td colspan="1" rowspan="1">Comments</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Segment Net Revenue:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Supply Chain Services</td>
<td colspan="1" rowspan="1">$590 million to $630 million</td>
<td colspan="1" rowspan="1">$560 million to $610 million</td>
<td colspan="1" rowspan="1">Increased midpoint $25 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Performance Services Excluding Contigo Health</td>
<td colspan="1" rowspan="1">$350 million to $380 million</td>
<td colspan="1" rowspan="1">$370 million to $410 million</td>
<td colspan="1" rowspan="1">Decreased midpoint $25 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Net Revenue Excluding Contigo Health</td>
<td colspan="1" rowspan="1">$940 million to $1.01 billion</td>
<td colspan="1" rowspan="1">$930 million to $1.02 billion</td>
<td colspan="1" rowspan="1">No change to midpoint</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$237 million to $253 million</td>
<td colspan="1" rowspan="1">$235 million to $255 million</td>
<td colspan="1" rowspan="1">No change to midpoint</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Net Income</td>
<td colspan="1" rowspan="1">$119 million to $129 million</td>
<td colspan="1" rowspan="1">Not previously disclosed</td>
<td colspan="1" rowspan="1">New disclosure</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">$1.26 to $1.34</td>
<td colspan="1" rowspan="1">$1.16 to $1.28</td>
<td colspan="1" rowspan="1">Increased midpoint $0.08</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted Weighted Average Shares</td>
<td colspan="1" rowspan="1">94 million to 96 million</td>
<td colspan="1" rowspan="1">Not previously disclosed</td>
<td colspan="1" rowspan="1">New disclosure</td>
</tr>
</tbody>
</table>
</figure>

Premier Expects FY25 Net Revenue Of $940M-$1.01B (Prior $930M-$1.02B) Vs $990.75M Est, Adj EPS Of $1.26-$1.34 (Prior $1.16-$1.28) Vs $1.29 Est

Earnings Misses

Premier Q2 2025 Adj. EPS $0.27 Misses $0.30 Estimate, Sales $240.266M Miss $243.217M Estimate

APAM

ATEN

COLM

CVRX

EGHT

ENVA

FLNG

GBDC

ICHR

IESC

INNV

INTA

JNPR

KLIC

KTCC

LARK

LUMN

MRCY

MTCH

MUFG

OSCR

Earnings Scheduled For February 4, 2025

<a href="https://jehoshaphatresearch.com/wp-content/uploads/2025/01/PINC-Research-Opinion-by-Jehoshaphat-Research-Jan-2025.pdf" title="https://jehoshaphatresearch.com/wp-content/uploads/2025/01/PINC-Research-Opinion-by-Jehoshaphat-Research-Jan-2025.pdf">https://jehoshaphatresearch.com/wp-content/uploads/2025/01/PINC-Research-Opinion-by-Jehoshaphat-Research-Jan-2025.pdf</a>?

Short Sellers

Watching Premier; Jehoshaphat Research Issues Report On Co, Announcing It Is Short On The Stock

Canaccord Genuity analyst Richard Close maintains Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) with a Hold and raises the price target from $19 to $21.

Canaccord Genuity Maintains Hold on Premier, Raises Price Target to $21

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Premier, Inc. - PINC

Premier, Inc. to Participate in Leerink Global Healthcare Conference on March 11, 2025

Premier Announces the Nation's 100 Top Hospitals®

Premier, Inc. to Report Fiscal 2025 Third-Quarter Results and Host Conference Call on May 6, 2025

Premier, Inc. Application Is Under Construction in Epic Toolbox

Premier, Inc. Declares Quarterly Cash Dividend

Premier, Inc. Reports Fiscal-Year 2025 Third-Quarter Financial Results

Premier, Inc. to Participate in BofA Securities Healthcare Conference on May 13, 2025

Premier, Inc. named as data source in HealthVerity Marketplace™ to expand real-world data access for life sciences research

Comments

Premier

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL